Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Gray Sheet

Executive Summary

Norwood, Massachusetts-based surgical anchor firm enters into agreement with Medicine Lodge Inc. to purchase "substantially all of the assets" of MLI's "suture anchor soft tissue reattachment business," including the patents to its threaded screw anchor. Terms of the deal, which is expected to close Dec. 14, were not released, but Mitek says that it will make an upfront payment to MLI, as well as additional payments contingent on "manufacturing, product development and sales objectives." MLI currently manufactures its threaded screw for Zimmer under a non-exclusive agreement. Mitek says that after the acquisition, Zimmer will continue to license the technology and will take over manufacturing in early 1995. The MLI facility in Logan, Utah will continue to manufacture the screw for sales by Mitek. Components for Mitek's current anchor technology also will be manufactured at the MLI plant

You may also be interested in...

Former Sandoz Executive Kellum Admits US Price-Fixing

Former Sandoz executive Hector Armando Kellum has admitted involvement in a US generic price-fixing conspiracy, the US Department of Justice has announced.

99 Days Until MDR: Time Is Running Out For Medtech As Risky, Volatile Future Looms

The last year of the run up to the full implementation of the MDR has been characterized by a flurry of new documents and measures, but industry is adamant that medtech is heading for a crisis that will impact industry and patients alike.

BrightGene Bets On Remdesivir Amid Patent Questions

Despite many uncertainties, Suzhou-based BrightGene sees a bet on generic remdesivir worthy of a $700,000 investment.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts